infecti
noninfecti
pulmonari
complic
remain
major
caus
morbid
mortal
within
allogen
hematopoiet
stem
cell
transplant
rapid
diagnosi
treatment
complic
improv
diagnos
may
difficult
clinic
symptom
radiolog
sign
reveal
case
nonspecif
furthermor
complic
rate
lung
biopsi
limit
use
even
highest
flexibl
bronchoscopi
fb
remain
tradit
initi
investig
method
patient
pulmonari
previou
studi
examin
use
fb
main
diagnost
method
hsct
popul
report
yield
howev
studi
variou
limit
small
sampl
size
inclus
nontranspl
autotranspl
popul
addit
method
detect
virus
fb
specimen
previou
studi
includ
viral
viral
identif
inclus
viral
antigen
use
direct
immunofluoresc
immunohistochem
method
low
posit
rate
requir
long
detect
time
prompt
sensit
test
need
identifi
specif
pathogen
therebi
allow
earli
administr
appropri
therapi
polymeras
chain
reaction
pcr
use
altern
diagnost
tool
studi
report
use
pcr
detect
variou
virus
fb
oren
et
report
use
pcr
seven
virus
diagnost
fb
brownback
et
report
use
pcr
two
virus
fb
aim
studi
retrospect
explor
clinic
efficaci
pcr
particularli
virus
conjunct
fb
patient
pulmonari
infiltr
consecut
patient
pulmonari
infiltr
underw
diagnost
fb
januari
decemb
includ
studi
patient
underw
one
fb
examin
consid
independ
patient
studi
comput
tomographi
ct
scan
chest
perform
prior
fb
pulmonari
infiltr
analyz
base
final
radiolog
report
indic
absenc
infiltr
presenc
focal
infiltr
affect
one
two
lobe
diffus
infiltr
affect
two
lobe
treatment
modif
defin
addit
discontinu
chang
antimicrobi
treatment
addit
system
corticosteroid
due
bronchoscop
result
within
day
fb
neutropenia
defin
absolut
neutrophil
count
progress
infiltr
result
respiratori
failur
death
within
day
follow
fb
record
mortal
studi
conduct
accord
declar
helsinki
protocol
approv
ethic
committe
peke
univers
peopl
hospit
patient
receiv
myeloabl
condit
regimen
mac
without
vitro
deplet
condit
therapi
modifi
buci
plu
atg
unrel
donor
urd
modifi
buci
ident
sibl
donor
isd
group
patient
isd
group
receiv
fresh
granulocyt
factor
unmanipul
bone
marrow
cell
addit
peripher
blood
stem
cell
pbsc
patient
urd
hsct
group
receiv
fresh
unmanipul
pbsc
patient
receiv
cyclosporin
mycophenol
mofetil
methotrex
gvhd
bronchoscopi
perform
respiratori
physician
use
flexibl
bronchoscop
olympu
procedur
perform
nasal
oral
caviti
follow
local
anesthesia
lidocain
support
cardiopulmonari
monitor
continu
assess
puls
rate
blood
pressur
oxygen
satur
fb
sampl
obtain
area
lung
infiltr
multipl
area
present
sampl
obtain
area
infiltr
sever
variou
flexibl
bronchoalveolar
procedur
includ
bronchoalveolar
lavag
bal
protect
sampl
brush
psb
transbronchi
biopsi
tbb
use
establish
diagnosi
decis
request
psb
tbb
made
respiratori
physician
respons
fb
among
patient
underw
multipl
fb
procedur
record
consid
independ
blood
fb
sampl
routin
subject
follow
test
gram
stain
fungal
stain
stain
bacilli
stain
ii
cytolog
examin
iii
bacteri
fungal
cultur
iv
galactomannan
gm
v
pcr
revers
transcript
pcr
detect
atyp
bacteria
eg
legionella
speci
mycoplasma
pneumonia
atyp
mycobacteria
pneumocysti
jirovecii
follow
virus
herpesvirus
hsv
type
cytomegaloviru
cmv
viru
ebv
varicella
zoster
viru
human
respiratori
virus
influenza
type
includ
b
parainfluenza
viru
coxsackieviru
respiratori
syncyti
viru
human
bocaviru
human
metapneumoviru
human
coronavirus
cov
human
rhinovirus
adenoviru
polyomavirus
bk
viru
jc
viru
parvoviru
enterovirus
noroviru
rotaviru
enteroviru
gener
type
enteroviru
cmv
ebv
test
result
show
viral
copiesml
fb
sampl
respect
defin
posit
pcr
virus
qualit
assist
microbiolog
serolog
analys
includ
follow
peripher
blood
cultur
sputum
cultur
serum
gm
serum
assay
pcr
virus
blood
bacteri
pneumonia
defin
presenc
posit
fb
cultur
andor
pcr
strong
clinic
suspicion
lower
respiratori
tract
infect
eg
presenc
fever
cough
purul
sputum
pleurisi
leukocytosi
fungal
pneumonia
defin
posit
fb
cultur
mold
rare
yeast
invas
pulmonari
aspergillosi
ipa
defin
accord
revis
eortcmsg
accept
posit
gm
blood
bal
sampl
bal
gm
test
consid
posit
threshold
valu
posit
cultur
aspergillu
speci
fb
sampl
consid
suffici
diagnos
pulmonari
aspergillosi
howev
fb
cultur
posit
candida
consid
suffici
diagnos
candida
pneumonia
unless
strongli
clinic
ground
suspici
radiolog
appear
good
clinic
respons
empir
antifung
agent
viral
pneumonia
defin
identif
presenc
clinic
symptom
pneumonia
ii
posit
fb
viru
pcr
respiratori
viru
iii
typic
imag
ct
featur
virus
addit
requir
posit
pcr
blood
meanwhil
ii
exclud
infecti
pneumonia
pneumocysti
jirovecii
pneumonia
pjp
defin
presenc
p
jirovecii
bodi
visual
silvermethenamin
stain
andor
p
jirovecii
dna
detect
pcr
bal
fluid
obtain
patient
establish
predispos
factor
typic
clinic
imag
ct
featur
polymicrobi
pulmonari
infect
defin
identif
two
infecti
agent
base
criteria
diagnost
yield
fb
consid
proport
case
specif
diagnosi
diffus
alveolar
hemorrhag
dah
defin
bal
sampl
increasingli
bloodi
return
three
separ
sampl
requir
presenc
data
censor
time
death
last
avail
continu
variabl
compar
use
u
test
categor
variabl
compar
use
test
fisher
exact
test
method
use
estim
probabl
os
univari
analysi
perform
use
binari
logist
regress
calcul
odd
ratio
confid
interv
ci
multivari
stepwis
logist
regress
analysi
use
assess
relationship
patient
characterist
posit
fb
result
p
consid
statist
signific
attempt
enter
variabl
univari
analysi
multivari
analysi
use
logist
regress
obtain
use
hypothesi
test
data
analys
conduct
primarili
use
statist
packag
social
scienc
spss
softwar
spss
inc
chicago
il
usa
total
diagnost
fb
perform
patient
januari
decemb
follow
techniqu
frequenc
appli
fb
bal
psb
tbb
bal
perform
twice
nine
patient
three
time
four
patient
basic
characterist
patient
shown
tabl
median
age
year
rang
year
common
hematolog
diagnosi
acut
myeloid
leukemia
aml
n
median
time
hsct
fb
day
rang
day
median
time
ct
fb
day
rang
day
patient
undergon
three
asymptomat
patient
refer
fb
abnorm
discov
incident
upon
ct
patient
n
fever
chest
symptom
cough
sputum
product
dyspnea
pleuriti
time
bronchoscopi
patient
n
neutropen
seven
patient
sever
neutropenia
anc
thrombocytopenia
common
median
platelet
count
rang
one
hundr
nineteen
ct
show
diffus
bilater
infiltr
patient
receiv
empir
antimicrobi
therapi
prior
fb
median
durat
antimicrobi
therapi
fb
day
rang
day
therapi
includ
antibiot
n
antifung
n
antivir
n
jirovecii
agent
n
thirti
patient
receiv
mechan
ventil
intens
care
unit
fb
tabl
show
detail
fb
result
overal
diagnost
yield
fb
includ
bal
psb
tbb
fb
reveal
case
noninfecti
etiolog
dah
case
diagnos
pulmonari
infect
result
impli
posit
fb
diagnos
pulmonari
infect
common
infecti
diagnosi
viral
pneumonia
viral
pneumonia
diagnos
pcr
virus
detect
time
cmv
commonli
detect
viru
n
second
common
viru
rsv
n
third
common
viru
parainfluenza
viru
n
fungal
pneumonia
diagnos
case
aspergillu
spp
fungal
pathogen
bacteri
pneumonia
diagnos
case
nonfer
bacteria
case
tubercl
bacillu
seven
case
one
case
legionella
pneumonia
one
case
tubercl
bacillu
tb
diagnos
pcr
pjp
diagnos
case
diagnosi
pjp
confirm
pcr
case
one
remain
case
organ
visual
direct
stain
polymicrobi
etiolog
establish
patient
two
microorgan
patient
three
microorgan
patient
four
microorgan
five
patient
aspergillu
spp
common
polymicrobi
pulmonari
infect
group
pathogen
also
identifi
assist
microbiolog
serolog
analys
patient
pathogen
accord
fb
result
differ
fb
result
posit
blood
cultur
univari
analysi
demonstr
p
ct
find
diffus
infiltr
p
plt
p
posit
assist
microbiolog
serolog
analys
p
statist
margin
associ
higher
likelihood
obtain
posit
fb
result
tabl
multivari
analysi
ct
find
diffus
infiltr
p
posit
result
assist
microbiolog
serolog
analys
p
significantli
associ
higher
likelihood
obtain
posit
fb
result
diagnost
yield
significantli
improv
patient
diffus
infiltr
compar
patient
focal
infiltr
vs
p
posit
result
assist
microbiolog
serolog
analys
associ
higher
likelihood
obtain
posit
fb
result
neg
result
p
overal
treatment
modif
fb
n
n
posit
fb
group
n
neg
fb
group
p
treatment
chang
consist
modif
antibiot
n
antifung
n
antivir
n
medic
addit
corticosteroid
n
overal
mortal
rate
n
posit
neg
fb
group
respect
p
one
patient
die
sudden
cardiac
arrest
patient
die
pneumonia
firstli
use
pcr
identifi
virus
fb
specimen
evalu
pulmonari
infiltr
patient
larg
studi
consecut
patient
overal
diagnost
yield
fb
fb
result
prompt
treatment
modif
case
percent
posit
fb
result
infect
polymicrobi
etiolog
establish
case
virus
common
infecti
diagnosi
follow
fungi
bacteria
p
jirovecii
attempt
combin
result
bal
psb
tbb
conjunct
pcr
enhanc
diagnost
yield
fb
compar
studi
report
diagnost
yield
howev
present
studi
demonstr
superior
diagnost
yield
sever
explan
may
account
outcom
first
small
size
psb
tbb
strict
definit
bacteri
viral
fungal
pneumonia
could
explain
higher
diagnost
yield
attain
present
studi
despit
use
wide
rang
molecular
diagnost
test
second
patient
receiv
empir
antimicrobi
therapi
prior
fb
potenti
decreas
diagnost
yield
fb
result
correspond
infecti
microorgan
overal
pathogen
consid
relev
mainli
virus
significantli
virus
detect
studi
previou
sever
explan
may
account
outcom
first
bacteri
fungal
infect
primari
caus
infect
neutropen
period
viral
infect
common
phase
major
patient
studi
second
compar
previou
studi
use
pcr
detect
virus
greatli
improv
diagnosi
virus
allow
earli
administr
appropri
therapi
howev
assay
avail
previou
studi
period
result
demonstr
pcr
fast
effect
diagnost
method
virus
studi
cmv
common
pathogen
found
agreement
previou
follow
rsv
parainfluenza
viru
aspergillu
pneumonia
account
fungal
pneumonia
common
polymicrobi
pulmonari
infect
group
may
correl
rel
higher
proport
studi
accord
previou
studi
threshold
valu
posit
bal
gm
studi
pjp
found
rel
high
percentag
studi
diagnosi
pjp
confirm
pcr
case
confirm
pcr
rel
sensit
detect
p
jirovecii
addit
gold
standard
method
direct
visual
pathogen
pcr
employ
current
studi
detect
p
jirovecii
dna
bal
establish
diagnosi
pjp
inde
direct
visual
posit
one
nine
patient
ultim
diagnos
pjp
pjp
case
posit
pcr
neg
smear
probabl
repres
colon
sinc
characterist
clinic
radiolog
pictur
pjp
observ
patient
moreov
previou
studi
confirm
pcr
assay
rel
sensit
highli
specif
detect
p
jirovecii
respect
low
rate
posit
predict
valu
bacteri
pneumonia
diagnos
case
strike
differ
studi
previou
studi
bacteri
pneumonia
significantli
high
percentag
tb
result
demonstr
tb
remain
signific
issu
china
even
current
progress
medic
scienc
consid
high
risk
lung
biopsi
low
posit
rate
sputum
smear
use
pcr
diagnos
tb
fb
specimen
safe
appropri
method
incid
dah
observ
consist
incid
report
fb
result
prompt
treatment
modif
case
higher
report
chang
frequent
identifi
modif
treatment
especi
antivir
treatment
modif
posit
fb
group
significantli
higher
neg
fb
group
signific
differ
mortal
rate
two
group
result
prove
pcr
fb
fast
effect
diagnost
method
identifi
virus
allow
earli
administr
appropri
therapi
therebi
elimin
pathogen
studi
show
diagnost
yield
fb
diffus
infiltr
better
focal
infiltr
consist
find
seneviratna
et
lanino
et
reason
result
may
diffus
infiltr
greater
probabl
infecti
caus
high
pathogen
burden
focal
infiltr
addit
notabl
differ
studi
compar
previou
report
group
posit
result
assist
microbiolog
serolog
analys
associ
higher
likelihood
obtain
posit
fb
may
also
explain
higher
probabl
infecti
basi
limit
studi
multifactori
first
retrospect
studi
second
import
limit
studi
consensu
regard
optim
time
fb
recipi
center
may
introduc
bia
third
although
defin
treatment
modif
chang
introduc
within
day
fb
definit
way
ensur
chang
accur
given
retrospect
natur
studi
final
studi
repres
incid
pneumonia
follow
would
requir
analysi
patient
new
pulmonari
infiltr
summari
larg
studi
firstli
use
pcr
identifi
virus
fb
sampl
evalu
pulmonari
infiltr
popul
confirm
fb
conjunct
pcr
effici
rapid
diagnosi
manag
pulmonari
infiltr
patient
none
huang
xu
contribut
studi
concept
design
tang
mo
perform
data
analysi
tang
wrote
manuscript
author
particip
provid
patient
data
